METASTATIC COLORECTAL CANCER

This study tests whether adding two targeted drugs (encorafenib and cetuximab) to standard immunotherapy (pembrolizumab) works better than immunotherapy alone for people with a specific genetic type of advanced colorectal cancer (BRAF V600E, MSI-H/dMMR) that has spread and hasn't…

This study compares two immunotherapy drugs (nivolumab alone or with ipilimumab) against standard chemotherapy in people with a specific type of advanced colorectal cancer (MSI-H/dMMR). The goal is to see which treatment better delays cancer growth and improves survival. About 83…

This study tests a new way to use existing drugs (panitumumab or cetuximab) to control metastatic colorectal cancer that has spread and cannot be removed by surgery. About 34 people with left-sided tumors will receive these drugs early in their treatment, with the goal of keeping…

This study was designed for people with advanced colorectal cancer that had stopped responding to standard treatments. It aimed to test a combination of two experimental immunotherapies (AlloStim and an anti-PDL1 drug) to see if they could shrink tumors or help people live longer…

This study aimed to test two immunotherapy drugs (tiragolumab and atezolizumab) plus targeted radiation in people with a type of metastatic colorectal cancer that doesn't respond to standard immunotherapy. The trial was withdrawn before any participants enrolled, so no results ar…

This study tests whether a new drug (MRTX849) combined with cetuximab works better than standard chemotherapy for people with advanced colorectal cancer that has a specific KRAS G12C mutation. About 461 adults whose cancer worsened after first treatment will be randomly assigned …

This study tests whether adding valproate (a drug used for seizures) to standard antibody therapy can help control metastatic colorectal cancer longer. About 38 adults with a specific genetic type (RAS wild type) will receive the combination after initial treatment. The goal is t…

This study tests whether a new combination of drugs (trifluridine/tipiracil plus bevacizumab) works better than the standard combo (capecitabine plus bevacizumab) for people with metastatic colorectal cancer who are not healthy enough for intensive chemotherapy. About 856 adults …

This phase 3 study compares a new immunotherapy drug called HX008 to standard chemotherapy as a first treatment for people with a specific type of advanced colorectal cancer (MSI-H/dMMR). The goal is to see which approach better delays cancer growth. About 190 adults with metasta…

This study tests two experimental drugs, AK112 and AK117, alone or together, in people with metastatic colorectal cancer that cannot be removed by surgery. The goal is to see if these drugs can shrink tumors or slow the disease. About 254 participants will be enrolled. The study …

This early-phase study tests a new treatment called WD-01, which uses a patient's own immune cells modified to target a protein (GCC) found on colorectal cancer cells. The goal is to see if it is safe and can shrink tumors in people with metastatic colorectal cancer who have not …

This early-phase study tests a new type of CAR-T cell therapy (REVO-UWD-01) for people with metastatic colorectal cancer that has spread. The treatment uses specially engineered immune cells to target a protein called GCC found on cancer cells. The main goals are to find a safe d…

This study tests whether a new drug called anlotinib, when combined with standard chemotherapy, works better than the usual treatment for people with a certain type of advanced colorectal cancer. About 748 adults with RAS/BRAF wild-type cancer that has spread and cannot be remove…

This study tests a new drug called onvansertib added to standard chemotherapy for people with advanced colorectal cancer that has certain gene mutations (KRAS or NRAS). About 113 participants will receive either the standard treatment or the standard plus onvansertib. The goal is…

This study was designed to see if adjusting the dose of a chemotherapy drug called 5-FU based on its level in the blood could improve treatment for people with metastatic colorectal cancer. It planned to enroll adults who had not yet received treatment for their advanced cancer. …

This study tests whether adding hydroxychloroquine (a malaria drug) to standard chemotherapy can improve treatment for people with advanced colorectal cancer that has spread. The drug targets cancer cells that survive initial treatment. About 155 participants will be screened, an…

This phase 2 study tests two experimental immunotherapy drugs, botensilimab alone or combined with balstilimab, against standard chemotherapy options for people with advanced colorectal cancer that has stopped responding to previous treatments. The goal is to see if these drugs c…

This study tests whether a special pressure-enabled catheter delivers radioactive tracer more precisely to liver tumors than a standard catheter. Twenty adults with liver cancer who are scheduled for radioembolization will receive both catheters during the mapping procedure. The …

This study looks at whether changes in tumor DNA found in the blood (ctDNA) can predict if chemotherapy is working in people with advanced colorectal cancer that no longer responds to standard treatments. About 103 participants will give blood samples and have regular scans to tr…